Priorities for the Priority Review Voucher.

Published

Journal Article

The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases. Under the voucher program, the developer of a drug for a neglected or rare pediatric disease that is approved by the U.S. Food and Drug Administration receives a bonus priority review voucher for another drug. As of 2016, four vouchers have sold for an average price of $200 million. Recent experience with the voucher program indicates strengths and weaknesses of the program, as well as a need for legislative changes.

Full Text

Duke Authors

Cited Authors

  • Ridley, DB

Published Date

  • January 2017

Published In

Volume / Issue

  • 96 / 1

Start / End Page

  • 14 - 15

PubMed ID

  • 27573624

Pubmed Central ID

  • 27573624

Electronic International Standard Serial Number (EISSN)

  • 1476-1645

International Standard Serial Number (ISSN)

  • 0002-9637

Digital Object Identifier (DOI)

  • 10.4269/ajtmh.16-0600

Language

  • eng